NCT04050709

QUILT-3.064: PD-L1 t-haNK In Subjects With Locally Advanced Or Metastatic Solid Cancers

Open-Label Phase 1 Study of PD-L1 t-haNK In Subjects With Locally Advanced Or Metastatic Solid Cancers

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 16 (actual)
• Sponsor: ImmunityBio, Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Phase 1 study to assess the safety, preliminary efficacy of PD-L1 t-haNK and to determine the maximal tolerated dose and designate the recommended phase 2 dose in subjects with locally advanced or metastatic solid cancers.

Detailed description

Phase 1 study to assess the safety, preliminary efficacy of PD-L1 t-haNK and to determine the maximal tolerated dose and designate the recommended phase 2 dose for subjects with locally advanced or metastatic solid cancers. The study will be conducted in 2 parts: part 1 will involve dose escalation and part 2 will involve expansion of the recommended phase 2 dose.

Conditions

• Locally Advanced Solid Tumor
• Metastatic Cancer
• Solid Tumor

Interventions

Type	Name	Description
BIOLOGICAL	PD-L1 t-haNK	PD-L1 t-haNK Suspension for Infusion

Timeline

• Start date: 2019-07-18
• Primary completion: 2021-03-30
• Completion: 2026-03-25
• First posted: 2019-08-08
• Last updated: 2026-04-01

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study